HC Wainwright Has Bullish Outlook for DTIL FY2030 Earnings

Key Points

• HC Wainwright raised its FY2030 EPS estimate for Precision BioSciences to $1.24 from $1.09 and maintained a “Buy” rating, while the current-year consensus remains a loss of $2.69 per share.
• Analyst sentiment is mixed but leans positive: four analysts rate DTIL a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $32.25.
• Precision BioSciences reported a quarterly EPS loss of $1.26, missing the $0.80 consensus estimate, and continues to post deeply negative profitability metrics despite institutional investors owning about 38% of the stock.

Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Equities researchers at HC Wainwright increased their FY2030 earnings per share estimates for shares of Precision BioSciences in a research report issued on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $1.24 for the year, up from their prior estimate of $1.09. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Precision BioSciences' current full-year earnings is ($2.69) per share.

Several other research analysts have also issued reports on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Precision BioSciences in a research report on Wednesday, August 5th. Wall Street Zen downgraded Precision BioSciences from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Oppenheimer started coverage on Precision BioSciences in a report on Tuesday, June 9th. They issued an "outperform" rating and a $20.00 target price for the company. Finally, JonesTrading reiterated a "buy" rating and set a $30.00 price objective on shares of Precision BioSciences in a research note on Friday, April 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $32.25.

Precision BioSciences Price Performance

NASDAQ:DTIL opened at $7.42 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 12.82 and a current ratio of 12.82. The company has a 50-day moving average of $7.42 and a 200-day moving average of $6.42. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $9.62. The company has a market capitalization of $204.79 million, a price-to-earnings ratio of -2.65 and a beta of 1.27.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%.

Institutional Trading of Precision BioSciences

Several large investors have recently made changes to their positions in DTIL. Empery Asset Management LP bought a new position in shares of Precision BioSciences in the fourth quarter worth about $9,130,000. Boothbay Fund Management LLC grew its stake in shares of Precision BioSciences by 497.1% during the fourth quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company's stock valued at $4,435,000 after purchasing an additional 887,515 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Precision BioSciences during the fourth quarter valued at approximately $3,320,000. Affinity Asset Advisors LLC acquired a new stake in shares of Precision BioSciences in the first quarter valued at approximately $3,289,000. Finally, Bleichroeder LP increased its holdings in shares of Precision BioSciences by 54.7% in the fourth quarter. Bleichroeder LP now owns 1,662,500 shares of the company's stock valued at $6,916,000 after purchasing an additional 587,500 shares in the last quarter. Institutional investors own 37.99% of the company's stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company's pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source